REGENERON PHARMACEUTICALS, INC. Intangible Assets, Net (Excluding Goodwill)
REGENERON PHARMACEUTICALS, INC. (REGN) had Intangible Assets, Net (Excluding Goodwill) of $1.31 billion as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization
us-gaap:IntangibleAssetsNetExcludingGoodwill · last filed 2026-07-30
- 2026-06-30: Intangible Assets, Net (Excluding Goodwill) $1.31B.
- 2026-03-31: Intangible Assets, Net (Excluding Goodwill) $1.29B.
- 2025-12-31: Intangible Assets, Net (Excluding Goodwill) $1.26B.
- 2025-09-30: Intangible Assets, Net (Excluding Goodwill) $1.38B.
| Period end | Intangible Assets, Net (Excluding Goodwill) |
|---|---|
| 2026-06-30 | $1.31B 10-Q · filed 2026-07-30 |
| 2026-03-31 | $1.29B 10-Q · filed 2026-04-29 |
| 2025-12-31 | $1.26B 10-Q · filed 2026-07-30 |
| 2025-09-30 | $1.38B 10-Q · filed 2025-10-28 |
| 2025-06-30 | $1.35B 10-Q · filed 2025-08-01 |
| 2025-03-31 | $1.17B 10-Q · filed 2025-04-29 |
| 2024-12-31 | $1.15B 10-K · filed 2026-02-04 |
| 2024-09-30 | $1.12B 10-Q · filed 2024-10-31 |
| 2024-06-30 | $1.10B 10-Q · filed 2024-08-01 |
| 2024-03-31 | $1.06B 10-Q · filed 2024-05-02 |
| 2023-12-31 | $1.04B 10-K · filed 2025-02-05 |
| 2023-09-30 | $1.02B 10-Q · filed 2023-11-02 |
| 2023-06-30 | $953.00M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $928.70M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $915.50M 10-K · filed 2024-02-05 |
| 2022-09-30 | $804.10M 10-Q · filed 2022-11-03 |
| 2021-12-31 | $6.70M 10-K · filed 2023-02-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |